Affordable Access

Access to the full text

Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms

Authors
  • Vijayvergia, Namrata1
  • Dasari, Arvind2
  • 1 Fox Chase Cancer Center, Philadelphia, PA, 19111, USA , Philadelphia (United States)
  • 2 University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA , Houston (United States)
Type
Published Article
Journal
Current Treatment Options in Oncology
Publisher
Springer US
Publication Date
Oct 07, 2020
Volume
21
Issue
12
Identifiers
DOI: 10.1007/s11864-020-00794-0
Source
Springer Nature
Keywords
License
Yellow

Abstract

Ongoing advances in our understanding of neuroendocrine tumor (NET) biology, genetics, and immunology, will continue to expand the availability of targeted therapies, thus improving the outcomes of patients. Well-differentiated neuroendocrine tumors (NETs) are grouped into pancreatic and non-pancreatic NETs (includes GI and thoracic NETs) for treatment considerations (Fig. 1). For panNETs, initial therapy is driven by the need of radiographic response, and targeted agents are typically reserved for second and third line based on the toxicity profile. Treatment options for non-pancreatic NETs are also expanding and while SSAs are the typical first-line option, everolimus and PRRT both remain approved therapies for future lines, and VEGF TKIs are showing promising results in research settings. Sequencing these agents and best time to incorporate peptide receptor radio therapy into the management algorithm remains an unmet need.

Report this publication

Statistics

Seen <100 times